Discover how the Accugenix Track and Trending tool aggregates critical EM data

CLIA Waiver for QuickVue® RSV Test

Quidel Corporation has announced that the U.S. Food and Drug Administration (FDA) granted CLIA waiver for the QuickVue® RSV test for the qualitative detection of respiratory syncytial virus (RSV).

The waiver makes the QuickVue RSV test more widely available for use, especially in physician offices and clinics where waived tests are used most frequently. The QuickVue RSV test is simple and accurate, with high sensitivity and specificity.

Respiratory syncytial virus is recognized by the American Academy of Pediatrics as the leading cause of pneumonia and bronchiolitis among children two years of age and younger. RSV is a common virus with symptoms that often resemble the common cold. The QuickVue RSV test is intended for use as an aid in the diagnosis of acute RSV viral infections for symptomatic pediatric patients.

NOTE: This item is from our 'historic' database and may contain information which is not up to date.

Source: Quidel Corporation View latest company information

Posted: March 7, 2008
Request Information
[will open your email client]

© 2001 - 2017 Rapid Test Methods Ltd • Please join us on Twitter, Facebook and LinkedIn • RSS Feed